急性肾损伤心血管患者的肾脏生物标志物：一例报告及文献综述
Renal Biomarkers in Cardiovascular Patients with Acute Kidney Injury: A Case Report and Literature Review.
作者信息
Claure-Del Granado Rolando, Chávez-Íñiguez Jonathan S
机构信息
Division of Nephrology, Hospital Obrero No 2-CNS, Cochabamba, Bolivia.
Instituto de Investigaciones Biomédicas e Investigación Social de la Facultad de Medicina (IIBISMED), Facultad de Medicina, Universidad Mayor de San Simon, Cochabamba C.P. 3119, Bolivia.
出版信息
Diagnostics (Basel). 2023 May 31;13(11):1922. doi: 10.3390/diagnostics13111922.
Biomarkers have become important tools in the diagnosis and management of cardiorenal syndrome (CRS), a complex condition characterized by dysfunction in both the cardiovascular and renal systems. Biomarkers can help identify the presence and severity of CRS, predict its progression and outcomes, and facilitate personalized treatment options. Several biomarkers, including natriuretic peptides, troponins, and inflammatory markers, have been extensively studied in CRS, and have shown promising results in improving diagnosis and prognosis. In addition, emerging biomarkers, such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, offer potential for early detection and intervention of CRS. However, the use of biomarkers in CRS is still in its infancy, and further research is needed to establish their utility in routine clinical practice. This review highlights the role of biomarkers in the diagnosis, prognosis, and management of CRS, and discusses their potential as valuable clinical tools for personalized medicine in the future.
生物标志物已成为诊断和管理心肾综合征（CRS）的重要工具，CRS是一种以心血管和肾脏系统功能障碍为特征的复杂病症。生物标志物有助于识别CRS的存在和严重程度，预测其进展和结果，并促进个性化治疗方案的制定。包括利钠肽、肌钙蛋白和炎症标志物在内的几种生物标志物已在CRS中得到广泛研究，并在改善诊断和预后方面显示出有前景的结果。此外，诸如肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白等新兴生物标志物为CRS的早期检测和干预提供了潜力。然而，生物标志物在CRS中的应用仍处于起步阶段，需要进一步研究以确定它们在常规临床实践中的效用。本综述强调了生物标志物在CRS诊断、预后和管理中的作用，并讨论了它们未来作为个性化医学有价值临床工具的潜力。
Zotero 插件